Media stories about Palatin Technologies (NYSE:PTN) have trended somewhat negative on Sunday, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Palatin Technologies earned a news sentiment score of -0.01 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.8489387121215 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Several analysts have weighed in on PTN shares. Zacks Investment Research downgraded Palatin Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 29th. Canaccord Genuity set a $6.00 target price on Palatin Technologies and gave the company a “buy” rating in a research note on Tuesday, May 16th.

Shares of Palatin Technologies (NYSE PTN) traded up 3.4171% during mid-day trading on Friday, reaching $0.4116. The company’s stock had a trading volume of 415,943 shares. The company has a 50 day moving average of $0.42 and a 200-day moving average of $0.39. Palatin Technologies has a 12 month low of $0.29 and a 12 month high of $0.90. The firm’s market capitalization is $62.89 million.

COPYRIGHT VIOLATION WARNING: “Palatin Technologies (PTN) Receives Daily Media Sentiment Rating of -0.01” was posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.watchlistnews.com/palatin-technologies-ptn-receives-daily-media-sentiment-rating-of-0-01/1511528.html.

About Palatin Technologies

Palatin Technologies, Inc is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.

Insider Buying and Selling by Quarter for Palatin Technologies (NYSE:PTN)

Receive News & Ratings for Palatin Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.